Related Experiment Video
Updated: May 4, 2026

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
Published on: July 23, 2012
Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis
Tommaso Gosetti di Sturmeck1, Leonardo Malimpensa2, Gina Ferrazzano3
1European Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.
Abstract:
The current hypothesis on the pathophysiology of multiple sclerosis (MS) suggests the involvement of both inflammatory and neurodegenerative mechanisms. Disease Modifying Therapies (DMTs) effectively decrease relapse rates, thus reducing relapse-associated disability in people with MS. In some patients, disability progression, however, is not solely linked to new lesions and clinical relapses but can manifest independently. Progression Independent of Relapse Activity (PIRA) significantly contributes to long-term disability, stressing the urge to unveil biomarkers to forecast disease progression. Twenty-five adult patients with relapsing-remitting multiple sclerosis (RRMS) were enrolled in a cohort study, according to the latest McDonald criteria, and tested before and after high-efficacy Disease Modifying Therapies (DMTs) (6-24 months). Through Agilent microarrays, we analyzed miRNA profiles from peripheral blood mononuclear cells. Multivariate logistic and linear models with interactions were generated. Robustness was assessed by randomization tests in R. A subset of miRNAs, correlated with PIRA, and the Expanded Disability Status Scale (EDSS), was selected. To refine the patient stratification connected to the disease trajectory, we computed a robust logistic classification model derived from baseline miRNA expression to predict PIRA status (AUC = 0.971). We built an optimal multilinear model by selecting four other miRNA predictors to describe EDSS changes compared to baseline. Multivariate modeling offers a promising avenue to uncover potential biomarkers essential for accurate prediction of disability progression in early MS stages. These models can provide valuable insights into developing personalized and effective treatment strategies.
Insights
Biomarkers in microRNA profiles can predict multiple sclerosis progression independent of relapse activity. This aids in personalizing treatment strategies for patients with relapsing-remitting multiple sclerosis.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
- Genomics
Background:
- Multiple sclerosis (MS) pathophysiology involves inflammation and neurodegeneration.
- Disease Modifying Therapies (DMTs) reduce relapses but not all disability progression.
- Progression Independent of Relapse Activity (PIRA) significantly impacts long-term disability.
Purpose of the Study:
- Identify microRNA (miRNA) biomarkers to predict PIRA in relapsing-remitting MS (RRMS).
- Develop models for stratifying patients based on disease trajectory.
- Enhance personalized treatment strategies for early MS stages.
Main Methods:
- Analyzed miRNA profiles from peripheral blood mononuclear cells of 25 RRMS patients before and after high-efficacy DMTs.
- Utilized Agilent microarrays for miRNA profiling.
- Employed multivariate logistic and linear models with randomization tests for analysis.
Main Results:
- Selected a subset of miRNAs correlated with PIRA and Expanded Disability Status Scale (EDSS) changes.
- Developed a robust logistic model predicting PIRA status with high accuracy (AUC = 0.971).
- Built a multilinear model using four miRNA predictors to describe EDSS changes.
Conclusions:
- Multivariate modeling of miRNA expression shows promise for predicting MS disability progression.
- Baseline miRNA profiles can stratify patients regarding PIRA risk.
- These findings support the development of personalized therapeutic approaches for MS.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023